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INTRODUCTION
Hastened engraftment after allogeneic transplantation
is a highly desirable objective. It decreases the risk of
infectious and bleeding complications, lessens the use of
antibiotics and blood products, and reduces hospitalization
and the procedure costs. Peripheral blood progenitor allo-
transplants produce more rapid hematologic reconstitution
than related [1,2] and unrelated bone marrow transplants
[3]. This results in higher overall survival, especially in
high-risk patients. In standard-risk patients, survival
appears similar to that after bone marrow transplantation
(BMT). A concern exists that peripheral blood stem cell
(PBSC) allotransplants may be fraught with a higher inci-
dence of chronic graft-versus-host disease (GVHD) [4,5].
Thus, for patients with standard risk, PBSC transplanta-
tions may offer inferior quality of life when compared with
BMT and may not have any clear advantage aside from
more rapid hematologic reconstitution. 
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ABSTRACT
Granulocyte colony-stimulating factor (G-CSF) priming increases the number of progenitor cells in harvested bone
marrow (BM) and has been used for allogeneic transplantation. Primed bone marrow (pBM) seems to offer faster
engraftment than steady-state BM, but the stability of such engraftment has been questioned. The incidence of
graft-versus-host disease (GVHD) and disease relapse after pBM, compared with such incidence after BM or
peripheral blood progenitor allotransplantation, has not been established. We studied the long-term outcome
(median follow-up, 24 months) of sibling matched allografting with G-CSF pBM. Seventeen patients received pBM
from matched sibling donors primed with G-CSF 10 µg/kg per day for 2 days before BM harvest. Conditioning con-
sisted of total body irradiation and cyclophosphamide (CY); busulfan and CY; or total lymphoid irradiation, CY, and
antithymocyte globulin. All infused grafts contained ≥3.5 to 4  108 mononuclear cells per kilogram. Ten of
17 patients received methotrexate as part of their GVHD prophylaxis. International Bone Marrow Transplant Reg-
istry definitions for engraftment were used. Control subjects consisted of 112 consecutive patients who received
allogeneic transplantation at our institution with steady-state BM; control subjects for length of hospitalization con-
sisted of the subset of patients who underwent transplantation during 1996. Neutrophil engraftment occurred a
median of 7 days earlier in primed bone marrow transplantation (pBMT) patients when compared with steady-state
BMT patients; this shortened hospitalization by a median of 11 days. The peritransplant mortality rate was 18% in
pBMT patients and 25% in BMT patients (not significant). The rate of GVHD of grade >II and the rate of relapse
were almost identical in pBMT and BMT patients (GVHD: 18% and 19%, respectively; relapse: 14% and 13%,
respectively). There were 4 transplant-related deaths within the first 100 days; 1 patient died of disease relapse on
day 470. Twelve patients remained alive on days 430 through 1522 after BMT. Results showed that pBM allografts
resulted in more rapid engraftment and shorter hospitalization. All patients maintained stable donor engraftment.
In this cohort of patients, G-CSF pBMT resulted in rates of GVHD, disease relapse, and peritransplant mortality
that were similar to those produced by conventional BMT.
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We demonstrated in a pilot study that granulocyte
colony-stimulating factor (G-CSF) priming before marrow
harvesting resulted in a graft with a higher progenitor cell
content, which produced rapid engraftment [6]. Two ran-
domized studies compared cytokine-primed bone marrow
(BM) and cytokine-mobilized PBSCs in the setting of
autologous transplants for non-Hodgkin’s lymphoma
(NHL) and found no significant differences in rate of
engraftment [7,8]. In mice BM, G-CSF priming markedly
increased repopulating capacity [9]. However, some investi-
gators have expressed serious concerns regarding the stabil-
ity of engraftment provided by primed bone marrow trans-
plantation (pBMT). In a study of 12 patients who
underwent allogeneic pBMT, 4 experienced delayed graft
failure (ie, between days 55 and 130), and 2 required a stem
cell (SC) boost. This was in contrast to an appropriate con-
trol group in which graft failure was not seen [10]. 
There are no studies addressing the incidence of
chronic GVHD and disease relapse after pBMT. Our previ-
ous study had a median follow-up of 265 days after trans-
plantation (range, 214-314 days) [6]. In this article we
report on long-term follow-up (ie, 1-5 years) in 17 patients
who underwent G-CSF pBMT at Mount Sinai Medical
Center, New York, NY.
MATERIALS AND METHODS
Patients and Conditioning
Seventeen patients underwent sibling matched BMT
between 1995 and 1998. Depending on the disease and proto-
col, conditioning consisted of either (1) total body irradiation
1500 cGy or busulfan (Bu) 16 mg/kg plus cyclophosphamide
(CY) 120 mg/kg or (2) total lymphoid irradiation 900 cGy
plus CY 200 mg/kg and antithymocyte globulin (Atgam;
Upjohn, Kalamazoo, MI) 80 mg/kg.
Priming and Transplantation
After signing an informed consent, all donors received
2 daily doses of 10 µg/kg G-CSF SCs on the 2 days before
harvest. For harvest, the target collection was 4  108
mononuclear cells (MNCs) per kilogram. The cell content
to estimate the volume of harvest was 2.2  108 MNCs per
mL bone marrow. The maximum volume collected was lim-
ited to 20 mL per kg of donor body weight. The number of
cells transplanted was adjusted to 3.5  108 MNCs/kg. No
manipulation was performed on the product other than red
cell or plasma depletion as required.
GVHD Prophylaxis and Supportive Therapy
GVHD prophylaxis included cyclosporin A (CsA 12
mg/kg/day) (tapered after day 120) and methotrexate (MTX)
in 10 patients (15 mg/m2 on day 1 and 10 mg/m2 on days 3,
6, and 11). MTX was withheld if the total serum bilirubin
concentration was >2 mg/dL. Seven patients with elevated
liver function test results received corticosteroids in addition
to CsA. Patients who did not receive MTX were given intra-
venous (IV) methylprednisolone sodium succinate (Solu-
Medrol; Pharmacia & Upjohn, Kalamazoo, MI) 0.5 mg/kg
per day on days 7 through 14 and 0.5 mg/kg twice per day on
days 14 through 28. On discharge, patients treated with
methylprednisolone sodium succinate received prednisone
(PRD), which was tapered according to the following sched-
ule: 0.8 mg/kg per day on days 29 through 43, 0.5 mg/kg per
day on days 44 through 56, 0.2 mg/kg per day on days 57
through 119, and 0.1 mg/kg per day on days 120 through
179. Intravenous -globulin 0.5 g/kg was given every
2 weeks starting on day 1. Supportive care included gut
decontamination, sterile laminar airﬂow (LAF) isolation, ﬂu-
conazole, high-dose IV acyclovir, and Pneumocystis carinii
pneumonia prophylaxis. Patients with diagnoses other than
acute myelocytic leukemia (AML) or chronic myelocytic
leukemia (CML) received G-CSF or granulocyte-macro-
phage colony-stimulating factor starting on day 0. Prophy-
lactic transfusions of platelets were given for a platelet count
of ≤10  109/L if no bleeding occurred and ≤50  109/L if
bleeding occurred. 
Engraftment, GVHD, Length of Hospitalization, and
Disease Relapse
Deﬁnitions for engraftment were as follows: the ﬁrst of
3 consecutive days with absolute neutrophil count (ANC)
>0.5  109/L and ANC >1  109/L and the ﬁrst of 3 con-
secutive days with platelet count >20  109/L after 1 week
without platelet transfusions. GVHD was graded as
described previously [11]. Donor chimerism was determined
by conventional cytogenetics, ﬂuorescence in situ hybridiza-
tion, variable number of tandem repeats analysis, or any
combination of the three. Length of hospitalization was cal-
culated from day of admission to day of discharge. 
Control patients for engraftment, GVHD, and peri-
transplant mortality consisted of 112 consecutive patients
who received allogeneic steady-state BMT at our institu-
tion; control patients for length of stay consisted of the sub-
set of patients who underwent transplantation in 1996.
Statistics
For engraftment, Kaplan-Meier plots were compared
using the log rank test. For GVHD, regimen-related mor-
tality, and disease relapse, the Mann-Whitney test was used.
RESULTS
Patients
Patient characteristics are summarized in Table 1. Sixteen
of the 17 patients had a Karnofsky performance score (KPS)
of 100%; 1 had a KPS of 80%. Twelve of the patients were
standard risk (ie, had chronic-phase CML, severe aplastic
anemia (SAA), AML, or NHL in ﬁrst complete remission),
and 5 were high risk (ie, had refractory lymphoma/leukemia
or accelerated-phase CML, or had undergone a previous
transplant). 
Follow-up data for analysis of GVHD were available for
16 patients; data regarding disease relapse were available for
13 patients. Ten of the 17 patients were previously described
after a median follow-up of 144 days (range, 48-585 days)
post BMT [6]. Fourteen patients were male, and 3 were
female. The median age was 38 years (range, 15-59 years).
All patients were genotypically identical with their sibling
donors at the HLA class I and II loci as assigned by family
studies. Nine had sex-matched and 8 had sex-mismatched
donors (5 female donor/male recipients, 2 with previous
pregnancies, and 3 male donor/female recipients). GVHD
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prophylaxis consisted of CsA/MTX in 10 patients and
CsA/PRD in 7 patients. Seven patients received growth fac-
tor support after transplantation. 
Characteristics of the control (BMT) group are summa-
rized in Table 2. This group was comparable to the study
group in median age, proportion of patients with CML, pro-
portion of patients receiving growth factor support, and ratio
of high-risk to standard-risk patients. The proportion of
patients receiving CsA/PRD was higher in the pBMT group.
Engraftment
The cell content and characteristics of stimulated and
unstimulated grafts have been described [6]. The means for
total nucleated count harvested and infused, and CD3+ and
CD34+ cells per kilogram recipient body weight were compa-
rable between the pBM and BM grafts. The number of gran-
ulocyte-macrophage colony-forming units per kg recipient
body weight was higher in pBM grafts (data not shown). 
The kinetics of engraftment and length of hospital stay
are illustrated in Figure 1. Neutrophil engraftment occurred
more rapidly in patients receiving pBM than in those receiv-
ing steady-state BM. The median time to an ANC of 500
was 17 and 24 days for pBMT and BMT patients, respec-
tively (P = .0003); median time to an ANC of 1000 was 19
and 26 days, respectively (P = .007). Faster engraftment
resulted in shortened median hospitalization (34 days) for
pBMT patients compared with BMT patients (45 days)
(P = .0005). Median time to a platelet count >20,000 was
21 days for pBMT patients and 25 days for BMT patients;
the difference, however, was not statistically signiﬁcant. 
Among patients who received pBMT, there were differ-
ences in days to an ANC of 500 and an ANC of 1000
according to whether patients received MTX as part of their
GVHD prophylaxis regimen. Because of the small number
of patients in each group, these differences were not signiﬁcant
but favored the group that did not receive MTX. Neverthe-
less, the cohort of patients receiving pBM and MTX fared
Table 1. Characteristics of Primed Bone Marrow Transplantation Patients (n = 17)*
UPN MTX Age, y Sex Diagnosis Donor Sex/Parity Conditioning Risk Day Post BMT Current Status
214 – 44 M NHL F TBI/CY H 1527 A
229 + 38 M CML/CP M TBI/CY L 76 D
231 + 35 M CML/CP M TBI/CY L 1422 A
254 – 24 M NHL F Bu/CY H 43 D
265 – 28 M SAA M TLI/CY/ATG L 1210 A
284 – 36 F AML M TBI/CY L 1100 A†
293 + 36 M CML/CP M TBI/CY L 1030 A
304 + 59 M CML/AP M TBI/CY H 91 D
307 + 15 F PNH M TBI/CY L 967 A
314 – 46 M HL/NHL M TBI/CY H 916 A
323 + 24 F SAA M TLI/CY/ATG L 867 A
350 – 54 M MM M TBI/CY H 470 D†
362 + 49 M MDS F TBI/CY H 24 D
366 – 38 M CML/CP M TBI/CY L 617 A
399 + 41 M SAA F/P TLI/CY/ATG L 454 A
400 + 43 M CML/CP M TBI/CY L 442 A
401 + 45 M CML/CP F/P TBI/CY L 435 A
*UPN indicates unique patient number; MTX, methotrexate; BMT, bone marrow transplantation; NHL, non-Hodgkin’s lymphoma; TBI, total
body irradiation; CY, cyclophosphamide; H, high; A, alive; CML/CP, chronic myelocytic leukemia, chronic phase; L, low; D, died; Bu, busulfan;
SAA, severe aplastic anemia; TLI, total lymphoid irradiation; ATG, antithymocyte globulin; AML, acute myelocytic leukemia; CML/AP, chronic
myelocytic leukemia, acute phase; PNH, paroxysmal nocturnal hemoglobinuria; HL, Hodgkin’s lymphoma; MM, multiple myeloma; MDS,
myelodysplastic syndrome; F/P, parous female.
†Relapsed.
Table 2. Characteristics of Control (Bone Marrow Transplantation)
Patients (n = 112)*
Characteristic
Median age (range), y 32 (1-63)
Risk, high/low 30/82
Diagnosis
ALL CR1 and CR2 10
AML CR1 and CR2 22
CML/CP 30











*Data are n unless otherwise speciﬁed. ALL indicates acute lymphocytic
leukemia; CR, complete remission; AML, acute myelocytic leukemia;
CML/CP, chronic myelocytic leukemia, chronic phase; AP, acute phase;
BC, blast crisis; SAA, severe aplastic anemia; TBI, total body irradiation;
CY, cyclophosphamide; Bu, busulfan; GVHD, graft-versus-host disease;
CsA, cyclosporine A; MTX, methotrexate; PRD, prednisone. 
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better than our historical controls. Interestingly, no obvious
differences were noted in median time to a platelet count
>20,000 or in length of hospitalization between pBMT
patients who did and did not receive MTX as part of their
GVHD prophylaxis (Figure 2).
Toxicity, Chimerism, GVHD, and Disease Status
All 17 patients completed conditioning and underwent
transplantation. Three patients in the high-risk group died
from severe veno-occlusive disease (1 each on days 24, 43,
and 94); full donor engraftment had occurred in the last
2 patients who succumbed. One patient in the low-risk
group died of thrombotic thrombocytic purpura/hemolytic
uremic syndrome on day 74; full donor engraftment had
occurred, and the patient had grade I skin GVHD. The
overall peritransplant mortality rate was 24% in pBMT
patients and 25% in BMT patients (not signiﬁcant). Twelve
patients remained alive at 435 to 1527 days after transplan-
tation. One patient in the high-risk group died from
myeloma relapse on day 470. One patient in the low-risk
group experienced an isolated central nervous system
relapse that was treated with craniospinal irradiation, sys-
temic chemotherapy, and donor leukocyte infusion on day
325. That patient remained in complete unsustained remis-
sion on day 1100; results of cerebrospinal ﬂuid tests at that
time were negative. 
The median follow-up time for pBMT patients was
862 days. Outcomes according to risk groups are summa-
rized in Table 1.
Of the 12 long-term survivors, 1 has a PS of 50% as a
result of chronic extensive GVHD; the remaining 11 have a
PS of 100%. The Kaplan-Meier estimate for event-free sur-
vival at 3 years is 58% for the pBMT group versus 48% for
control (BMT) patients (P = .08) (data not shown). Mortal-
ity at day 100, the rate of acute GVHD of grade II through
IV, and the relapse rate were similar in pBMT patients and
controls (Table 3). One patient in the pBMT group has
chronic extensive GVHD.
Figure 1. Kaplan-Meier plots of engraftment comparing the number of primed bone marrow transplantation (BMT) (——) and steady-state BMT
(- - -) patients with absolute neutrophil counts (ANCs) of 0.5  109/L and 1.0  109/L, platelets >20  109/L, and length of hospitalization in the 2
groups. SCT indicates stem cell transplantation.
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DISCUSSION
In a previous report we described early outcome in
10 patients who underwent pBMT. This pilot study had a rel-
atively short follow-up (median, 144 days; range, 48-585 days)
after BMT [6], and therefore, late graft failure, which has
been reported by other investigators [10], remained a valid
concern. Furthermore, chronic GVHD often occurs a year or
more after transplantation, and the data in our previous report
were not adequate to estimate its prevalence. The current
study, which has a longer follow-up time and incorporates a
larger group of patients, confirms that pBM hastens neu-
trophil recovery, and the difference in such recovery between
pBMT and conventional BMT is statistically signiﬁcant. 
A caveat of our study is the fact that a higher proportion
of patients in the control group received MTX for GVHD
prophylaxis. As demonstrated in Figure 2, MTX partially
blunts the advantage of pBM in terms of neutrophil recov-
ery. There were not enough control patients receiving
CsA/PRD or enough patients in the two pBM subgroups to
allow for meaningful subset comparisons. However, such
comparisons are a highly desirable goal and should be part
of a future randomized study.
At 1 to 5 years of follow-up, full donor engraftment is
seen in all patients without indication of primary or sec-
ondary graft failure, as described by Mavroudis et al. [10].
There are two possible reasons for this discrepancy. First, in
the Mavroudis study, the grafts were subjected to T-cell
depletion by positive CD34+ selection, which resulted in sub-
stantial loss of progenitor cells. The dose infused was 2 to 3
times lower than that given to our patients (0.82 to 3.1 
106/kg versus 3 to 20  106/kg) [6,10]. In addition, T-cell
depletion is known to result in occasional graft failure. Sec-
ond, our protocol was designed to use a very short course (2
days) of G-CSF before harvesting, whereas the study by
Mavroudis et al. used a standard (5-day) regimen of G-CSF
peripheral blood progenitor mobilization. Our rationale for
using a short course of G-CSF was based on the fact that
the number of CD34+ cells in peripheral blood peaks after
4 to 6 days of cytokine treatment. This probably coincides
with an efﬂux of progenitor cells from the marrow. It was
our hope that using a short course of G-CSF would maxi-
mize proliferation and minimize mobilization.
As expected, hospital discharge was more rapid in the
group of patients receiving pBM. This could not be attrib-
uted to changes in transplant care, as the control group used
was chosen because those patients’ admission time over-
lapped with that of the cohort studied. Primed BM involves
a modest added cost for the cytokine used in the donor, but
this cost is clearly offset by the shortened hospitalization. 
An additional concern involves the administration of
G-CSF to healthy individuals, especially siblings of myeloid
leukemia patients. Our protocol called for follow-up blood
cell counts at 1, 6, and 12 months after harvest in donors.
More revealing will be the results of a current National Mar-
row Donor Program study that involves long-term follow-up
of donors after a 5-day G-CSF mobilization regimen. 
The current study does not allow firm conclusions in
terms of disease relapse because of the heterogeneity of
patients and controls. However, there have been no relapses
in the limited number of patients with chronic-phase CML
who received pBM. Overall survival after pBMT compared
with survival after BMT or PBSC allotransplants requires
further examination in randomized studies using donor/recip-
ient age-, sex-, and disease-matched case-control subjects.
Our patient cohort exhibited an incidence of GVHD
that was strikingly similar to that seen in our historical con-
trols who underwent transplantation with sibling matched
BM. Because the follow-up time in both groups is relatively
long, the respective incidences are not expected to vary
signiﬁcantly with additional follow-up. Although it is con-
ceivable that with larger accrual, pBMT may show a differ-
ent pattern of acute or chronic GVHD than BMT, currently
both procedures appear similar in producing minor anti-
gen–related GVHD.
The change from BM to PBSCs as a source of reconsti-
tution for autologous SC transplantation resulted in dra-
matic improvement in transplantation-related mortality and
had a major impact on the outcome of such transplants.
However, outcomes after allogeneic transplantation are also
affected by other factors such as GVHD and graft-versus-
Figure 2. Median days to absolute neutrophil count (ANC) of 0.5 
109/L, ANC of 1.0  109/L, and platelet count of 20  109/L; and
median length of hospitalization. Patients who underwent steady-state
bone marrow transplantation ( ); patients who underwent primed
bone marrow transplantation and who did ( ) and did not ( ) receive
methotrexate as part of graft-versus-host disease prophylaxis. 
Table 3. Acute GVHD, Mortality at Day 100, and Disease Relapse in
pBMT Patients and Control Subjects*
pBMT Steady-State BMT
% n % n
Acute GVHD ≥ grade II 19 3/16 19 19/101
Mortality at day 100 24 4/17 25 28/112
Disease relapse 15 2/13 13 11/84
Data are median (range) or n. 
*GVHD indicates graft-versus-host disease; pBMT, primed bone mar-
row transplantation.
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leukemia effects. Therefore, the success rate with the use of
PBSCs will be a result of the interaction of these variables
with hematologic and immune reconstitution. At this point
there is no convincing evidence that, for patients with SAA,
early chronic-phase CML, or AML in first remission and
without comorbidities, PBSC allotransplants are superior to
BM transplants, with the exception of faster engraftment.
Primed BM may offer the engraftment advantages of PBSCs
and the lower incidence of GVHD seen with BM. Manipu-
lation of PBSCs by, for instance, positive CD34+ selection,
may lower the incidence of GVHD. However, carefully
designed studies are needed to determine whether such an
approach results in a higher incidence of disease relapse.
BM harvesting has the distinct disadvantages of requir-
ing anesthesia and operating room time. In donors with
poor venous access, BM harvest circumvents the risks of a
central line. Our priming regimen involves a shorter expo-
sure to cytokines for healthy donors than that used for
PBSC mobilization. The safety record of G-CSF in
healthy donors is quite remarkable, but minimal exposure
to cytokines may be desirable in relatives of patients with
myeloid disorders. This study supports the need for a ran-
domized study comparing G-CSF–primed BM versus
G-CSF–mobilized PBSCs in patients with low transplanta-
tion risk. BM priming with other cytokines appears to be a
reasonable avenue of investigation.
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